Barclays Keeps Their Buy Rating on Encompass Health (EHC)

In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Encompass Health, with a price target of $140.00.

Claim 55% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Mok CFA is an analyst with an average return of -3.2% and a 50.19% success rate. Mok CFA covers the Healthcare sector, focusing on stocks such as Encompass Health, Brookdale Senior Living, and Centene.

In a report released yesterday, Truist Financial also reiterated a Buy rating on the stock with a $140.00 price target.

Based on Encompass Health’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.59 billion and a net profit of $194.5 million. In comparison, last year the company earned a revenue of $1.46 billion and had a net profit of $151.5 million

Based on the recent corporate insider activity of 89 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EHC in relation to earlier this year. Most recently, in March 2026, Edmund Fay, the Sr. Vice Pres. and Treasurer of EHC sold 11,937.00 shares for a total of $1,277,259.00.